Case Summary (G.R. No. 215104)
Key Dates
Alleged transactions took place in May 1996. Anonymous complaint dated May 15, 1996; Office of the Ombudsman resolution finding probable cause dated December 4, 1996. Sandiganbayan decision convicting petitioners dated April 29, 2014 and denial of motions for reconsideration dated October 24, 2014. Supreme Court decision on consolidated petitions rendered March 18, 2021. (1987 Constitution applied, as decision date is after 1990.)
Applicable Law
Primary criminal statute: Section 3(e) of Republic Act No. 3019 (Anti‑Graft and Corrupt Practices Act). Constitutional principle invoked: presumption of innocence under the 1987 Constitution and the requirement that criminal liability be proven beyond reasonable doubt. Evidentiary and procurement principles (public bidding rules and standards for proof of overpricing) informed the analysis.
Factual Background — Transactions
DOH‑NCR purchased: (a) 10,000 bottles of Paracetamol Suspension 60 ml (125 mg/5 ml) from Aegis Pharmaceuticals at P25.00 per bottle (total P250,000), delivery and payment actions in May 1996; and (b) 1,500 bottles of Ferrous Sulfate 250 mg with Vitamin B complex and Folic Acid from Lumar Pharmaceutical Laboratory at P220.00 per bottle (total P330,000), delivered and paid in May 1996. The Ombudsman investigation was triggered by an anonymous letter alleging irregular procurement and overpricing.
Procedural History
Informations were filed in the Sandiganbayan (Criminal Cases Nos. 26492 and 26493) charging the DOH‑NCR officials and suppliers with violation of Section 3(e) R.A. No. 3019 for giving unwarranted benefits and causing undue injury to the government by awarding overpriced contracts and facilitating payment. The cases were jointly tried; petitioners pleaded not guilty. The Sandiganbayan convicted most accused in both cases, acquitted one, and imposed penalties including imprisonment and perpetual disqualification from public office. Motions for reconsideration were denied, prompting consolidated Rule 45 petitions to the Supreme Court.
Prosecution Theory and Evidence
The prosecution’s primary assertions: (1) the purchased medicines were overpriced relative to prevailing prices in DOH bid documents, (2) purchases were made without public bidding where bidding was required, and (3) petitioners acted with evident bad faith and manifest partiality, giving unwarranted benefits to Aegis and Lumar and causing quantified financial prejudice (P193,700.00 for Paracetamol; P219,945.00 for Ferrous Sulfate). Documentary evidence relied upon included a DOH‑Central “Price List for the eleven (11) hospitals” (January–June 1996) and a 1994 Abstract of Bids; fact‑finding reports and witness testimony from Ombudsman investigators and DOH/BAC personnel were also offered.
Defense Case and Evidence
The defense presented testimony and documents to show: (1) differences in product specifications (paracetamol syrup vs. suspension) that justify price differentials; (2) that Aegis or Lumar were prior winning bidders in earlier DOH‑NCR biddings and that DOH‑NCR practice permitted use of prior bidding results or negotiated repeat orders when a new bid schedule was not yet available; (3) that some procurements were emergency or repeat orders and supported by requisitions, stock position sheets, certificates of acceptance and other routine documents; (4) explanations on product formulation and production costs by supplier witnesses; and (5) lack of available originals for certain DOH or BFAD records due to retention/disposal policies. Defense witnesses included DOH officers, supplier representatives, and a BFAD official.
Sandiganbayan Findings and Basis of Conviction
The Sandiganbayan found all elements of Section 3(e) satisfied: that petitioners were public officers; that they acted with evident bad faith or manifest partiality by procuring overpriced medicines without public bidding; and that their acts gave unwarranted benefits to private suppliers and caused quantifiable damage to the government. The trial court based its findings primarily on comparisons using the DOH‑Central price list (for Paracetamol) and the 1994 Abstract of Bids (for Ferrous Sulfate), and treated petitioners’ signatures on requisitions, purchase orders and vouchers as indicative of conspiracy and assent.
Issue on Review
Whether the Sandiganbayan erred in convicting petitioners of violating Section 3(e) R.A. No. 3019, given the record on conspiracy, evident bad faith/manifest partiality, overpricing, and proof of undue injury/unwarranted benefits.
Standard of Review and Evidentiary Foundation
The Supreme Court emphasized the constitutional presumption of innocence and the need for proof beyond reasonable doubt. While respecting trial court findings, the Court will reverse where facts were misappreciated or where the prosecution failed to prove essential elements to the requisite moral certainty. The Court reasserted that a conviction under Section 3(e) cannot rest solely on procurement irregularities; it requires proof of corrupt motive (evident bad faith or manifest partiality) and demonstrable undue injury or unwarranted benefits causally linked to that corrupt intent.
Conspiracy — Legal Requirements and Court’s Assessment
Conspiracy requires an agreement of two or more persons to commit a felony plus overt acts evidencing a common purpose. Mere signatures, routine approvals, or performance of official duties do not, by themselves, establish a conscious agreement to commit the crime. The Court applied its precedent (Arias, Magsuci, Sabiniano, Maamo, et al.) to hold that the Sandiganbayan’s reliance on signatures on RIVs, POs, certificates of acceptance, and DVs was insufficient to prove conspiracy beyond reasonable doubt. The record lacked evidence of overt acts showing coordinated, intentional planning or moral ascendancy; thus the conspiracy theory failed.
Evident Bad Faith and Manifest Partiality — Legal Meaning and Application
Evident bad faith requires a palpable, fraudulent, or dishonest purpose; manifest partiality signifies a clear, notorious inclination to favor a private party. The Court stressed these are distinct, demanding states of mind and cannot be inferred merely from mistakes, lapses, or rule violations. Applying Sistoza, Sabaldan and subsequent jurisprudence, the Court found the prosecution did not establish that petitioners acted with corrupt intent rather than pursuant to an honest, though possibly mistaken, adherence to DOH practice (using prior bidding results or conducting emergency/repeat purchases). The DOH‑NCR practice of relying on prior winning bidder results, acknowledged by prosecution witnesses, and petitioners’ representation that the POs expressly referenced prior DOH‑NCR biddings, undercut any inference of conscious wrongdoing.
Proof of Overpricing and Quantification of Undue Injury
To prove overpricing, the prosecution must canvass identical goods (same brand, specifications, packaging) among multiple suppliers and produce reliable comparative data. The Court reiterated precedent (Caunan, Miranda, Sajul) that comparisons must be of the same product and supported by a canvass or signed quotations; reliance on secondary summaries or single-company quotations is insufficient. Here, the DOH‑Central Price List and the 1994 Abstract of Bids proffered by the prosecution were not shown to be reliable, comparable evidence of identical product pricing: (a) the DOH‑Central price list was a photocopy, admitted without establishing admissibility of secondary evidence, and it was prepared on May 24, 1996 — after DOH‑NCR’s May 10, 1996 Paracetamol purchase and with no proof it was received by DOH‑NCR; (b) the price list did not establish that the lower prices pertained to the same suspension product (the prosecution itself admitted syrup and suspension are different), and suppliers tied to the lower prices were not properly shown to supply an identical product; (c) the 1994 Abstract of Bids was an inadequate basis to conclude Lumar’s Ferrous Sulfate was overpriced because testimony and a Notice of Award supported that Lumar had validly won the 1994 bidding and that a competing lower bid either pertained to a different compound or was from a disqualified bidder. Because the prosecution failed to establish identity of items and a proper canvass, the alleged amounts of undue injury were not proven to moral certainty.
Admissibility and Weight of Documentary Evidence
The Court noted procedural shortcomings: prosecution offered photocopies (e.g., DOH‑Central Price List) without establishing exceptions to the best‑evidence rule or laying a proper foundat
Case Syllabus (G.R. No. 215104)
Procedural Posture
- Consolidated Petitions for Review on Certiorari under Rule 45 assail: the Sandiganbayan Special Fifth Division Decision dated April 29, 2014 and its Resolution dated October 24, 2014.
- Sandiganbayan convicted petitioners in Criminal Case No. 26492 and Criminal Case No. 26493 for violation of Section 3(e) of R.A. No. 3019 (Anti-Graft and Corrupt Practices Act).
- Petitioners before the Supreme Court included Majarais, Cabrera, Du, Agustin, Perez, Ocampo, Camposano and Macairan across the consolidated dockets identified in the caption.
- The Office of the Solicitor General (OSG) filed consolidated Comments urging affirmance of the Sandiganbayan's findings.
- The Supreme Court issued a decision dated March 18, 2021 (Caguioa, J.), reversing and setting aside the Sandiganbayan Decision and Resolution and acquitting the petitioners.
Factual Background — Procurement Transactions
- Two procurements by Department of Health — National Capital Region (DOH‑NCR) in 1996 form the subject matter:
- Purchase of 10,000 bottles of Paracetamol Suspension 60 ml, 125 mg/5 ml (Paracetamol Suspension), procured in May 1996 from Aegis Pharmaceuticals.
- Purchase of 1,500 bottles of Ferrous Sulfate 250 mg with Vitamin B Complex and Folic Acid, procured in May 1996 from Lumar Pharmaceutical Laboratory (Lumar).
- An anonymous letter dated May 15, 1996 to the Office of the Ombudsman complained of alleged irregularities in these DOH‑NCR purchases and implicated pharmaceutical suppliers including Aegis and Lumar.
- The Office of the Ombudsman, on December 4, 1996, issued a Resolution finding probable cause to charge the DOH‑NCR officials and suppliers with violation of Section 3(e) of R.A. No. 3019.
Informations and Allegations
- Criminal Case No. 26492 (Paracetamol Suspension from Aegis):
- Information alleges that on or about May 4, 1996 (or prior/subsequent thereto) Majarais (Director IV), Camposano (Financial Management Chief II), Cabrera (Administrative Officer III), Du (Accountant III), Agustin (Accountant I), Perez (Supply Officer III), together with Anthony M. Ocampo (owner of Aegis), conspired and acted with evident bad faith to give unwarranted benefits to Aegis.
- Alleged overprice: P25.00 per bottle (total P250,000.00) when prevailing price per DOH price list was P5.63 per bottle (total P56,300.00), yielding alleged damage P193,700.00.
- Allegation includes facilitation of payment and release of check No. 0000032668 on May 13, 1996 (related to DV No. D1269-96-0572).
- Criminal Case No. 26493 (Ferrous Sulfate from Lumar):
- Information alleges that on or about May 13, 1996 (or prior/subsequent thereto) Majarais, Camposano, Cabrera, Agustin and Perez, with Macairan (owner/proprietor of Lumar), acted with evident bad faith and manifest partiality to give unwarranted benefits to Lumar.
- Alleged overprice: P220.00 per bottle (total P330,000.00) when another supplier offered same product at P73.37 per bottle (total P110,055.00), yielding alleged damage P219,945.00.
- Allegation includes purchase without public bidding and facilitation of payment (DV No. D1269-96-05-78; check No. 0000032670 released May 13, 1996).
Pre‑trial Stipulations of Facts
- Parties stipulated to multiple documentary and factual matters for each criminal case, including:
- Positions held by each DOH‑NCR official at the material times (e.g., Majarais as Director IV; Cabrera as Administrative Officer III; Camposano as Financial Management Chief II; Agustin as Accountant I; Du as Accountant III; Perez as Supply Officer).
- Dates and existence of Requisition and Issue Vouchers (RIVs) dated March 4, 1996 for both procurements.
- Purchase Orders dated May 3, 1996 prepared in favor of Aegis (10,000 bottles Paracetamol at P25.00/bottle) and Lumar (1,500 bottles Ferrous Sulfate at P220.00/bottle).
- Deliveries by Aegis and Lumar on May 10, 1996 and certificates of acceptance executed May 13, 1996.
- Preparation of Disbursement Vouchers and release of corresponding checks on May 13, 1996.
- Accused Ocampo identified as owner of Aegis; Accused Macairan identified as owner/proprietor of Lumar.
- Accused Agustin admitted stipulation with qualification regarding participation in delivery/certificate of acceptance for Lumar transaction.
Prosecution Evidence — Witnesses and Highlights
- Purita S. Danga (former District Health Officer and OIC of DOH‑NCR during Majarais' suspension):
- Identified Majarais, Cabrera and Du in court.
- Recalled reading RIVs dated March 4, 1996 signed by Majarais and Cabrera and DV No. D1269-95-05-78.
- Testified that the usual mode of medicine procurement in DOH‑NCR is public bidding conducted by Committee on Bids and Awards (BAC).
- Admitted lack of personal knowledge of the transactions and that her knowledge about Majarais’ suspension came from reading a suspension order.
- Rogelio A. Ringpis (resident Ombudsman at DOH in 1996):
- Received anonymous letter dated May 15, 1996; conducted fact‑finding investigations; obtained procurement documents from Procurement and Logistics Service.
- For Paracetamol: obtained RIV (March 4, 1996), PO for 10,000 bottles, Aegis delivery receipt, Invoice No. 0129, descriptive inspection report, narrative report, certificate of acceptance by Perez.
- For Ferrous Sulfate: obtained PO dated May 3, 1996, RIV dated May 4, 1996, sales invoice, inspection reports, certificates of acceptance signed by Perez and Du.
- Concluded overpricing:
- Paracetamol allegedly overpriced at P25.00 vs. P5.63 per DOH price list for eleven hospitals (January–June 1996) — computed overprice P193,700.00.
- Ferrous Sulfate allegedly overpriced at P220.00 vs. P73.37 per 1994 abstract of bids — computed overprice P219,945.00.
- Acknowledged procedural differences between fact‑finding and formal preliminary investigation; did not send notices to accused due to preventive suspension policy.
- Admitted not examining each bid or seeking information on Foramen's disqualification or Lumar's exclusive distributorship and did not examine DOH‑NCR prior purchasing records for Paracetamol.
- Normita A. Palisoc (member of BAC for DOH):
- Described DOH public bidding procedure, technical evaluation and BAC responsibilities.
- Identified and testified about the "price list for the eleven (11) hospitals (January to June, 1996) December 19, 1995 public bidding" which she signed; explained that it lists winning bidders and serves as reference/guideline for offices without their own bidding results.
- Stated Item No. 278 shows a bid offer of P9.50 for Paracetamol 125 mg/5 ml 60 ml syrup/suspension and that previous price was P5.63; testified the BAC did not award the P9.50 bid because it exceeded allowable variance over previous price.
- Testified DOH‑Central price list was prepared on May 24, 1996 and that when there is delay in issuance, previous price list is automatically extended — thus Paracetamol price on May 10, 1996 should have been P5.63 (previous bidding price).
- Clarified BAC DOH‑Central has no supervisory control over regional BACs; DOH‑regional offices may have procurement modes separate from DOH‑Central.
Defense Evidence — Witnesses and Highlights
- Ma. Teresita Florentino Ocampo (Assistant General Manager, Aegis; wife of Anthony Ocampo):
- Testified Aegis received PO dated May 3, 1996 for Paracetamol suspension at P25.00/bottle and delivered after verifying stock.
- Explained notation on PO “subject to the terms and conditions of RFO NCR public bidding for drugs and medicines 1995 public bidding” and that Aegis had been awarded in the DOH‑NCR July 10, 1995 public bidding for Paracetamol suspension at P25.00 per 60 ml bottle, with Notice of Award dated August 16, 1995 and deliveries August–December 1995.
- Presented PO, Invoice No. 129, Delivery Receipt No. 055 dated May 10, 1996, inspection reports and certificate of acceptance as proof of delivery and acceptance.
- Explained practice of single performance bond per notice of award, reused for subsequent POs; produced DV evidence showing 80% payment initially and that balance paid after BFAD analysis.
- Maintained difference between Paracetamol syrup and suspension, presented bottles and asserted Delamo’s P5.63 bid in June 1995 Central Office bidding referred to syrup, not suspension, and argued three separate biddings (eleven hospitals, DOH Central Office, DOH NCR) produced differing winners and prices.
- Insisted P5.63 in eleven hospitals price list related to syrup won by Delamo in DOH Central Office bidding, not to suspension bid by Aegis at P25.00.
- Engr. David M. Masiado, Jr. (Officer‑in‑Charge, Material Management Division, DOH):
- Received letters from Ocampo requesting bidding documents and price lists; searched but could not locate such documents, explained office policy to dispose of documents after five or ten years.
- Identified reply dated November 9, 2009 to Ocampo’s requests.
- Rosalinda U. Majarais (accused; former Regional Director):
- Identified Memorandum dated September 11, 1995 endorsing pricelist for July 10, 1995 DOH‑NCR public bidding as basis for procurement; stated s